Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Kliniska effekter och biomarköreffekter av depå medroxiprogesteronacetat hos kvinnor med sicklecellssjukdom (SCD Depo)

2 november 2026 uppdaterad av: Andrea Roe, MD, MPH, University of Pennsylvania

This research is being conducted to see if using an injectable contraception, Depot Medroxyprogesterone Acetate (Depo-Provera), can reduce the pain experienced by women with sickle cell disease.

Participants in this study will be adult women with sickle cell disease who regularly experience sickle cell pain. They will complete a 3-month "baseline "with no use of hormonal contraception, and then a 3-month follow-up after receiving an injection of Depo-Provera. Participants will complete 6 to 7 in-person visits with a urine pregnancy test, blood draw, and surveys, as well as complete remote weekly surveys and monthly home pregnancy tests.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

65

Fas

  • Fas 4

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Georgia
      • Atlanta, Georgia, Förenta staterna, 30322
        • Har inte rekryterat ännu
        • Emory University
        • Kontakt:
    • Pennsylvania
      • Philadelphia, Pennsylvania, Förenta staterna, 19104
        • Rekrytering
        • Children's Hospital of Philadelphia
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 50 år (Vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Kvinna

Beskrivning

Inclusion Criteria:

  1. Provision of signed and dated informed consent form
  2. Female, aged 18-50 years old
  3. Diagnosis of sickle cell disease (SS, SB0,SB+,SC)
  4. Report of at least 1 vaso-occlusive pain episode per month on average in the previous 6 months
  5. At least 1 and no more than 10 medical presentations (e.g. hospitalization, emergencyroom visit, outpatient infusion visit) for vaso-occlusive pain during the past year, unless approved by study PI Andrea Roe
  6. Willing to discontinue any hormonal contraception at the time of enrollment. Washout period of 1 month since last use of all hormonal contraception, and 4 months since most recent administration of depot medroxyprogesterone, is required prior to enrollment in the study.
  7. Have regular menstrual cycles (when not on hormonal contraception) with a usual length of 21 to 35 days.
  8. Stable dose of hydroxyurea and other sickle cell-related medications for the past 6 months
  9. Access to a device with text-messaging capability
  10. Must be able to read and understand English
  11. Willing to comply with study procedures

Exclusion Criteria:

  1. Chronic inflammatory conditions, such as lupus or inflammatory bowel disease
  2. History of VTE or stroke
  3. Current use of crizanlizumab, voxelotor, or chronic transfusion therapy, including simple transfusion and red cell exchange transfusion, history of hematopoietic stem cell transplantation
  4. Current use of hormonal contraception or the copper intrauterine device
  5. Current pregnancy or pregnancy within the last 6 months
  6. Current lactation
  7. Polycystic ovary syndrome or irregular periods
  8. Blood pressure >= 160 systolic or >=100 diastolic at screening visit
  9. Has a history or current evidence of any condition, therapy, or other circumstance that in the opinion of the investigator exposes the participant to risk through participating in the trial, may confound the results of the trial, or could interfere with participation for the full duration of the trial.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Depot Medroxyprogesterone Acetate (Depo-Provera)

All participants will receive a 150mg dose intramuscular administration of depot medroxyprogesterone acetate (DMPA) injectable suspension after a 3-month baseline with no hormonal contraception.

150mg dose intramuscular administration of depot medroxyprogesterone acetate (DMPA) injectable suspension

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Frequency of acute vaso-occlusive episodes
Tidsram: 6 months

The primary outcome is frequency of VOEs during each phase (baseline and intervention). A VOE is self-reported by the participant.

During both the baseline and intervention study phases, participants will provide weekly reports via electronic survey of vaso-occlusive pain. VOE will be defined as self-reported typical SCD pain that interferes with usual daily activities or requires emergency care or hospitalization, with distinct episodes separated by at least one week without pain.

6 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
C-reactive protein
Tidsram: 6 months

C-reactive protein will be measured from blood samples drawn twice, once during each study phase (baseline and intervention).

6 months
Hemoglobin
Tidsram: 6 months

Hemoglobin will be measured from blood samples drawn twice, once during each study phase (baseline and intervention).

6 months
Reticulocyte count
Tidsram: 6 months

Reticulocyte count will be measured from blood samples drawn twice, once during each study phase (baseline and intervention).

6 months
Platelet count
Tidsram: 6 months

Platelet count will be measured from blood samples drawn twice, once during each study phase (baseline and intervention).

6 months
Fetal hemoglobin
Tidsram: 6 months

Fetal hemoglobin will be measured from blood samples drawn twice, once during each study phase (baseline and intervention).

6 months
Bilirubin
Tidsram: 6 months

Bilirubin will be measured from blood samples drawn twice, once during each study phase (baseline and intervention).

6 months
D-dimer
Tidsram: 6 months

D-dimer will be measured from blood samples drawn twice, once during each study phase (baseline and intervention).

6 months
von Willebrand factor
Tidsram: 6 months

von Willebrand factor will be measured from blood samples drawn twice, once during each study phase (baseline and intervention).

6 months
Pain intensity
Tidsram: 6 months

Pain intensity, as measured by the PROMIS Pain Intensity 1a Numeric Rating Scale, comparing baseline and intervention phases.

6 months
Pain intensity
Tidsram: 6 months

Pain intensity, as measured by the PROMIS Pain Intensity 3a scale, comparing baseline and intervention phases.

6 months
Pain interference
Tidsram: 6 months

PROMIS pain interference 8a scale, comparing baseline and intervention phases.

6 months
Number of vaso-occlusive pain days
Tidsram: 6 months

Number of vaso-occlusive pain days as measured in the study diary, comparing baseline and intervention phases.

6 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Andrea Roe, MD MPH, University of Pennsylvania

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

26 juni 2025

Primärt slutförande (Beräknad)

31 juli 2028

Avslutad studie (Beräknad)

31 juli 2028

Studieregistreringsdatum

Först inskickad

23 oktober 2024

Först inskickad som uppfyllde QC-kriterierna

28 oktober 2024

Första postat (Faktisk)

30 oktober 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

5 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

2 november 2026

Senast verifierad

1 maj 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

After the study is completed, the de-identified, archived data will be transmitted to the NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC) for use by other researchers including those outside of the study.

Tidsram för IPD-delning

Data will be made available starting 6 months after publication. There is no planned end date.

Kriterier för IPD Sharing Access

Researchers will obtain access through NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC) in accordance with their SOPs.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • CSR

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Ja

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera